2.81
+0.34(+13.77%)
Currency In USD
| Previous Close | 2.47 |
| Open | 2.48 |
| Day High | 2.98 |
| Day Low | 2.48 |
| 52-Week High | 7.85 |
| 52-Week Low | 1.29 |
| Volume | 2.94M |
| Average Volume | 1.59M |
| Market Cap | 308.3M |
| PE | -2.4 |
| EPS | -1.17 |
| Moving Average 50 Days | 2.14 |
| Moving Average 200 Days | 4.01 |
| Change | 0.34 |
If you invested $1000 in Annexon, Inc. (ANNX) since IPO date, it would be worth $158.22 as of July 03, 2025 at a share price of $2.81. Whereas If you bought $1000 worth of Annexon, Inc. (ANNX) shares 3 years ago, it would be worth $749.33 as of July 03, 2025 at a share price of $2.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
GlobeNewswire Inc.
Jun 18, 2025 8:05 PM GMT
Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program Shown to S
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 8:05 PM GMT
BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammat
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
GlobeNewswire Inc.
May 19, 2025 8:05 PM GMT
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations Poster Presentatio